Diagnosis of Pancreatic Cancer by Purine Metabolite (Hypoxanthine, Xanthine) in Urine

Last updated: February 26, 2024
Sponsor: Ho-Seong Han
Overall Status: Active - Recruiting

Phase

N/A

Condition

Pancreatic Cancer

Digestive System Neoplasms

Treatment

Purine metabolite (Hypoxanthine, Xanthine) in urine by CubeBio

Clinical Study ID

NCT06291779
SNUBH-GS- HBP5
E-2211-792-350 (local IRB)
  • Ages 18-80
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

  • This study aim to develope a diagnostic method of pancreatic cancer by using a reagent for analyzing purine metabolite (Hypoxanthine, Xanthine) in urine.

  • It is safe and cost effective compare to radiologic or blood test. It can be used for initial screening test for healty population.

Eligibility Criteria

Inclusion

  1. pancreatic cancer group Inclusion Criteria:
  • Pancreatic ductal adenocarcinoma that is pathologically confirmed or showscharacteristic radiologic features
  • Patients with resectable pancreatic cancer at the time of surgery (Includingborderline resectable pancreatic cancer at the time of diagnosis or Locallyadvanced pancreatic cancer after chemotherapy or radiation therapy)
  • Patients without invasion of adjacent organs other than the left adrenal glandand mesocolon
  • Patients with informed consent

Exclusion

Exclusion Criteria:

  • History of other malignancy (Inclusive if there is no evidence of recurrenceafter 5 years of treatment)
  • Patient with Inflammatory disease(e.g. severe pancreatitis, cholangitis)
  • Patients with underlying diseases at high risk of general anesthesia
  • Other subject whom the investigator deems inappropriate
  1. control group Inclusion Criteria included healthy individuals as well as patients withbenign diseases. Exclusion criteria for the control group included a previous cancer diagnosis within thepast five years, active inflammatory diseases, borderline malignant pancreatic tumors, or apostoperative pathological finding of malignancy.

Study Design

Total Participants: 120
Treatment Group(s): 1
Primary Treatment: Purine metabolite (Hypoxanthine, Xanthine) in urine by CubeBio
Phase:
Study Start date:
November 30, 2022
Estimated Completion Date:
May 31, 2024

Study Description

  • CubeBio and Seoul National University Bundang Hospital signed a joint technology development agreement to compare the analytical performance of existing analytical methods and purine metabolite analysis reagents developed by CubeBio.

  • Through quantitative analysis of hypoxanthine and xanthine in the urine of normal people and pancreatic cancer patients, we plan to confirm the possibility of diagnosing pancreatic cancer using reagents for analyzing purine metabolites.

  • Early diagnosis of pancreatic cancer is a key determinant of cure and survival rates, and impact on all aspects of cancer, including rate of progression, treatment, and prognosis.

  • This study could change the paradigm of pancreatic cancer screening by evaluating the stability and accuracy of urinary purine metabolite analysis reagents.

Connect with a study center

  • Ho-Seong Han

    Seongnam, Gyeonggi-do
    Korea, Republic of

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.